【摘要】 目的:探讨硫氧还蛋白-2(TRX-2)基因表达在急性白血病(AL)微小残留病灶(MRD)监测中的价值。方法:采用实时荧光定量聚合酶反应(RQ-PCR)检测AL初发组(68例)、血液学完全缓解(CHR)组(57例)和复发组(25例)TRX-2基因表达的变化,25名骨髓捐献者作为正常对照组,TRX-2基因表达量的上限(91)为参考值上限,回顾分析复发组在CHR期(骨髓原始细胞计数<5%)TRX-2基因表达的水平,比较其与流式细胞术(FCM)检测的MRD的相关性。结果:TRX-2基因表达在完全缓解组与初治组和复发组之间差异有统计学意义(P<0.01);复发患者CHR期(骨髓原始细胞<5%),21例(21/25)TRX-2基因呈高表达(>91),与流式细胞术检测的MRD具有相关性(r=0.874,P=0.0005)。结论:TRX-2基因为急性白血病新的广谱标志,适用于MRD的监测。更多还原

【Abstract】 Objective: To investigate the significance of human thioredoxin-2(TRX-2) in monitoring minimal residual disease(MRD) in acute leukemia(AL).Methods: We used real-time quantitative PCR to serially quantitize TRX-2 expression levels in the bone marrow of AL patients at diagnosis(n=68),at complete hematologic remission(CHR,n=57) and at relapse(n=25).Another 25 normal donors served as normal controls.The upper limit of the bone marrow at 91 was regarded as the reference.TRX-2 expression level at CHR with <5% blast cells in the bone marrow of relapse patients was analyzed and compared with MRD by flow cytometry.Results: The TRX-2 levels between the CHR patients and newly diagnosed patients,and between the CHR patients and the relapse patients had significant difference.TRX-2 expression level of 21(21/25) relapse patients at CHR with <5% blast cells in the bone marrow was higher than the reference(>91).TRX-2 level was correlated to the expression level of MRD.Conclusion: TRX-2 may be the marker for AL and used in MRD monitoring.更多还原